2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

The communicative effectiveness survey-revised (CESR): An objective measure of communicative participation for people with Parkinson’s disease

N.J. Donovan (Baton Rouge, LA, USA)
The condition of cerebral hemodynamics in the secondary vascular parkinsonism

D. Akramova, A. Umarov, G. Rakhimbaeva, M. Ataniyazov, D. Shosaidova (Tashkent, Uzbekistan)
The contribution of the subthalamic nucleus in gait initiation of subjects with Parkinson’s disease

C. Palmisano, G. Arnulfo, N.G. Pozzi, A. Canessa, A. Leporini, C.A. Frigo, G. Pezzoli, F. Steigerwald, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)
The core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD): Tolerability of preoperative neuropsychological testing for deep brain stimulation in Parkinson’s disease

G.D. Pal, V. Persinger, B. Bernard, B. Ouyang, C. Goetz, L. Verhagen (Chicago, IL, USA)
The correlation between dietary fiber, fluid intake and constipation in patients with Parkinson’s disease

N. Kawashima, A. Tabata, A. Kumon, K. Miyashita, A. Sato, H. Onuma, S. Nakamura, E. Horiuchi, K. Hasegawa (Fujisawa, Japan)
The correlation between N30 SEP and motor function in Parkinson’s disease

S.Y. Kang, Y.J. Kim, Y.H. Sohn, H.I. Ma (Hwaseong, Korea)
The differentiated treatment of Parkinson’s disease in patients with concomitant diabetes mellitus(DM) type 2

F.S. Akhmedova, M.K.U. Tukhtamishev (Tashkent, Uzbekistan)
The distinguishing clinical features of rapid-onset-parkinson-dystonia (RDP) syndrome due to ATP1A3 mutations

I.A. Meijer, R.A. Ortega, D. Raymond, N. Lubarr, V. Shanker, W.L. Severt, S. Bressman, L. Ozelius, R. Saunders-Pullman (New York, NY, USA)
The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale

L.S. Croll, K.M. Montgomery, C.V. Kulick, M.J. Nirenberg (New York, NY, USA)
The effect of a structured medication review on quality of life in patients with Parkinson’s disease. An interim analysis

A. Verbeek, N. Oonk, E. Munster, K. Movig, K. ter Huurne, H. Nijmeijer, J. van der Palen, L. Dorresteijn (Eerbeek, Netherlands)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z